<DOC>
	<DOC>NCT00974584</DOC>
	<brief_summary>This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of oral (PO) GDC-0941 administered with one of three planned regimens: Arm A: paclitaxel and carboplatin in bevacizumab-ineligible NSCLC patients, Arm B: paclitaxel, carboplatin, and bevacizumab in bevacizumab-eligible NSCLC patients and Arm C: pemetrexed, cisplatin, and bevacizumab in bevacizumab-eligible, non-squamous NSCLC patients.</brief_summary>
	<brief_title>A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically or cytologically documented NSCLC with advanced disease (Stage IIIb not eligible for chemoradiotherapy or Stage IV or recurrent disease) Adequate organ function as assessed by laboratory tests Evaluable disease or disease measurable per Response Evaluation Criteria in Solid Tumors (RECIST) More than one anticancer regimen (chemotherapy or radiotherapy) for advanced NSCLC prior to initiation of study treatment Any adjuvant or neoadjuvant anticancer therapy within a specified timeframe prior to first study treatment History of Grade &gt;= 3 fasting hyperglycemia or diabetes requiring regular medication Active autoimmune disease, active infection requiring IV antibiotics, or other current uncontrolled illness History of clinically significant cardiac or pulmonary dysfunction History of malabsorption syndrome or other condition that would interfere with enteral absorption Clinically significant history of liver disease Any condition requiring fulldose anticoagulants, such as warfarin, heparin, or thrombolytic agents Known brain metastases that are untreated, symptomatic, or require therapy Pregnancy, lactation, or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>PI3K</keyword>
	<keyword>Avastin</keyword>
</DOC>